HOME >> BIOLOGY >> NEWS
Interim data suggest major response with Aranesp(R) in anemic patients with MDS

THOUSAND OAKS, Calif., Jul 06, 2005 (BUSINESS WIRE) -- Amgen Inc. (NASDAQ:AMGN), the world's largest biotechnology company, today announced new interim data from a Phase 2 study evaluating the use of 500 mcg of Aranesp(R) (darbepoetin alfa) every three weeks to treat anemia in patients with a bone marrow disorder known as myelodysplastic syndromes (MDS). The data were presented at the 17th International Symposium of the Multinational Association of Supportive Care in Cancer (MASCC) in Geneva. (Abstract #02-007)

"The majority of MDS patients develop clinically significant anemia during the course of their disease, which often leads to fatigue and increased red blood cell transfusions," said Janice Gabrilove, M.D., professor of medicine, hematology and medical oncology at Mount Sinai School of Medicine, New York and the study's lead investigator. "In this study, low risk MDS patients receiving Aranesp every three weeks, who had no prior erythropoietic therapy, exhibited an overall response of 77 percent, increased hemoglobin levels and improvements in patient reported fatigue."

Results of an interim analysis were presented from the first 100 patients of an approximately 200 patient, Phase 2, single arm study of low risk MDS patients (those with a low risk of progressing to acute myeloid leukemia) with anemia and treated with Aranesp 500 mcg administered every three weeks. Of the 100 patients evaluated, 63 percent had no prior erythropoietic agent use. The primary endpoint of the study was the proportion of patients achieving an erythroid response (defined in accordance with the International Working Group Response Criteria) during the 13-week test period. Secondary endpoints included changes in hemoglobin level from baseline, incidence of transfusions and impact on patient reported fatigue.

Results were presented for all 100 patients for incidence of transfusion and patient reported fatigue and 90 patients were evaluated for erythroid respon
'"/>

Contact: Trish Hawkins
plange@amgen.com
805-447-5631
Porter Novelli
6-Jul-2005


Page: 1 2 3 4

Related biology news :

1. Interim analysis of anti-cancer vaccine, BiovaxID, to be conducted
2. Interim Aranesp data suggest major response in anemic patients with MDS
3. Interim long-term follow-up data show AMG 531 increases platelets in patients with ITP
4. Features of replication suggest viruses have common themes, vulnerabilities
5. New study suggests Concord grape juice may provide protection against breast cancer
6. Study suggests estrogen deficiency can lead to obesity-induced high blood pressure after menopause
7. Experiment suggests limitations to carbon dioxide tree banking
8. Immunity in social amoeba suggests ancient beginnings
9. New model for autism suggests women carry the disorder and explains age as a risk factor
10. Pediatric ritalin use may affect developing brain, new study suggests
11. Oldest DNA ever recovered suggests earth was warmer than previously believed

Post Your Comments:
(Date:10/28/2014)... Individual differences in moving activity in a novel ... to angling, according to an experimental study completed ... Finnish Game and Fisheries Research Institute. The study ... groups and authentic angling trials to analyse if ... trout reared in traditional and enriched hatchery rearing ...
(Date:10/27/2014)... a scientific one-two punch with a pair of papers ... sticky ends. , Collagen is the most common protein ... fibrous tissues that support cells and hold organs together. ... for tissue engineering and cosmetic and reconstructive medicine. , ... synthetic collagen for a decade, teasing out the details ...
(Date:10/27/2014)... day, about a third of blacks hold onto sodium ... an hour after the stress that raised their pressure ... know how chronic mental stress, obesity, and inflammation conspire ... the best ways to treat it. , "We ... – these patients have increased damage to their hearts, ...
Breaking Biology News(10 mins):Fish 'personality' linked to vulnerability to angling 2'Sticky' ends start synthetic collagen growth 2'Sticky' ends start synthetic collagen growth 3Researchers look for the best way to help shake too much sodium 2Researchers look for the best way to help shake too much sodium 3Researchers look for the best way to help shake too much sodium 4
(Date:10/27/2014)... 27, 2014 Pressure BioSciences, Inc. (OTCQB: ... in the development and sale of high pressure-based ... market, today announced that Professor Ruedi Aebersold ... highly reproducible, and robust method to allow – ... analysis on small needle biopsy samples by mass ...
(Date:10/27/2014)... 27, 2014 Investor-Edge has initiated ... NBIX ), Insmed Inc. (NASDAQ: ... ), Dyax Corporation (NASDAQ: DYAX ), and ... companies can be accessed at: http://investor-edge.com/register . ... ended at 4,483.72, up 0.69%, the Dow Jones Industrial ...
(Date:10/26/2014)... The report "Protective Coatings Market by Resin Type, ... Forecast to 2019", defines and segments the global protective ... and value generated. The protective coatings consumption is projected ... KT by 2019, at a CAGR of 9.52% during ... and 22 figures spread through 219 slides and in-depth ...
(Date:10/25/2014)... California (PRWEB) October 23, 2014 ... a specialty pharmaceutical company devoted to bringing new ... partnerships in 2015. , ViaDerma has developed an ... allows for rapid mass transfer of pharmaceutical active ... body to provide immediate localized therapy. The transdermal ...
Breaking Biology Technology:Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 2Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 3Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 4Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 5Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 2Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 5Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 2Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 3Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 4ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3
Cached News: